Down syndrome, or trisomy 21, is caused by the presence of a third copy of the 21st chromosome. Affected individuals have ...
Precision BioSciences, Inc. (NASDAQ:DTIL) revealed initial results from the first administration of PBGENE-HBV in cohort 1, ...
Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...
Market OverviewThe Global RNA Therapeutics Market is valued at USD 13.3 Billion in 2023 and is projected to reach a value ...
Precision BioSciences (DTIL) announced initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
A new lipid nanoparticle system can deliver messenger RNA (mRNA) to the brain via intravenous injection. | Drug Discovery And ...
Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...
The Mt. Sinai study could open the door to future therapies for Alzheimer’s, amyotrophic lateral sclerosis, brain cancer, and ...
Scientists have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature ...
Jax Bari, an 11-year-old from Philadelphia, shows me a photo of himself. It's hard to look at; in it, he's sprawled out on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results